English | Korean
The results of our accredited human clinical trial with a total of 56 subjects proved the safety and efficacy of Ganoderma Applanatum along the following results after 8 weeks of the trial:
The fasting blood sugar of the test group experienced a 69% reduction compared to control group
The blood sugar level decreased by 86.2%, two hours after meal consumption, in the test group compared to the control group
1) The world’s first invented Ganoderma Applanatum using mycelium extraction. “They are relatively less toxic products and are rich in bioactive compounds, such as polysaccharides, proteins, minerals, and other nutrients. Beneficial activities associated with mushroom fruiting
bodies and mycelia include antitumor, antimutagenic, antiviral, and antioxidant activities”
2) Our product yields significant levels of Beta-glucan. Beta-glucan is a type of soluble fiber found naturally in a variety of food sources, such as oats, barley, and rye. It’s associated with numerous health benefits, including lower cholesterol levels and improved immune health.
3) Our product, in capsule form, meets the high standards of Health Canada
”Kohei Suruga, Tsuyoshi Tomita and Kazunari Kadokura. Medicinal Mushroom Mycelia: Characteristics, Benefits, and Utility in Soybean Fermentation. November 29, 2021. DOI: 10.5772/intechopen.102522
HEILENEX ACHEIVEMENTS
Publications:
- THE KOREAN JOURNAL OF FOOD AND NUTRITION. Vol. 26. No.3.366-374(2013)
Journal of Natural Products, 67, 1110-1113 (2004)/ American Chemical Society and American Society of Pharmacognosy Archives of Pharmacal Research, 29, 479-483 (2006) - Phytotherapy Research, 19, 477-480 (2005)
- Biological and Pharmaceutical Bulletin, 28, 1103-1105 (2005)
Clinical Trials:
- Several animal studies (rats, dog, hamster and mice) were conducted in 2008.
-
Human clinical trial was conducted in 2012
-
Statistically significant results were achieved, demonstrating that our product is safe and effective in the treatment of type 2 diabetes without negative side effects.
- The results of our accredited human clinical trial with a total of 56 subjects proved the safety and efficacy of Ganoderma Applanatum along the following results after 8 weeks of the trial:
The fasting blood sugar of the test group experienced a 69% reduction compared to control group
The blood sugar level decreased by 86.2%, two hours after meal consumption, ni the test group compared to the control group
Analysis
- DNA testing of the Ganoderma Applanatum completed in 2014
- Composition Analysis of the Gandoerma Applanatum completed in 2015
- Analysis proved our species of Ganoderma Applanatum is 99% pure and is free from toxins, coliform group, e-coli, heavy metals and pesticides Intellectual Property
Patents
- Heilenex Pharma is the first and only company to hold a patent utilizing Ganoderma Applanatum for the treatment of diabetes.
- Two patents are filed under the World Intellectual Property Organization:
- Two patents are filed under the United States Patent and Trademark Office:
US 7595055 (B2) – US 7192591 (B2) - In 2017, Heilenex Pharma successfully obtained the Natural and Nonprescription Health Product Directorate (NNHPD) license from Health Canada supporting the distribution of our product and our claim, “contributes to healthy blood sugar levels and provides for healthy glucose metabolism”. glucose metabolism’ Source of fungal polysaccharides with immunomodulating properties. (2023)
- Title: Pharmaceutical composition comprising and extract or compounds isolated from elfvingia applanata for the prevention and the treatment of diabetes and diabetic complications
- Title: Pharmaceutical composition comprising and extract of elfvingia applanata for the prevention and the treatment of diabetes and diabetic complications
